Abstract

The hyperbranched biodegradable dendrimer (Boltron® H40) has received mounting attention as a result of its efficient encapsulation of therapeutic molecules and sustained release of the payloads into target cancer cells. Herein, we report the Boltron® H40 dendrimer conjugated with polyethylene glycol (PEG) and cRGDfc peptide ligand (i.e., H40-PEG-cRGDfc) for higher loading and targeted delivery of Docetaxel (DTX) to breast cancer cells. The characterization of synthesized nanoparticles was carried out by dynamic light scattering (DLS), 1H NMR, Fourier transform infrared spectroscopy (FT-IR), and differential scanning calorimetry (DSC). The H40-PEG-cRGDfc exhibited higher DTX encapsulation with 49.83 % drug loading. Interestingly, the DTX release profile of H40-PEG-cRGDfc showed a higher release of DTX at the acidic pH of 5.0 compared to physiological pH. The targeted H40-PEG-cRGDfc nanoparticles showed higher internalization ability towards breast cancer cell lines MDA-MB-231 and 4T1. The toxicity study of targeted and non-targeted NPs on NIH-3T3 normal mice cell line showed no apparent toxicity to the cells. The treatment of DTX-loaded targeted NPs (DTX-H40-PEG-cRGDfc) on MDA-MB-231 (IC50 10.06 nM) and 4T1 (IC50 8.67 nM) cell lines confirmed significant anti-breast cancer activity of designed formulation. This study demonstrated that cRGDfc targeted, DTX loaded, Boltron® H40 dendrimer had a significant breast cancer cell-killing ability. The experimental findings of this study displayed future opportunities for developing a targeted nano-therapeutic platform in breast cancer treatment.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.